Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | PBRM1 Y106* |
Therapy | Ipilimumab + Nivolumab |
Indication/Tumor Type | clear cell renal cell carcinoma |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
PBRM1 Y106* | clear cell renal cell carcinoma | predicted - sensitive | Ipilimumab + Nivolumab | Case Reports/Case Series | Actionable | In a clinical study, Opdivo (nivolumab) and Yervoy (ipilimumab) combination treatment resulted in complete response in a patient with renal clear cell carcinoma harboring PBRM1 Y106* (PMID: 29301960). | 29301960 |
PubMed Id | Reference Title | Details |
---|---|---|
(29301960) | Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. | Full reference... |